Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats

Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats

Objective(s): Uterine ischemia is a common problem with ongoing controversy about its pathogenesis and prevention. The present study aimed to investigate the protective role of sitagliptin against uterine ischemia-reperfusion injury (IRI). Materials and Methods: Rats were allocated into 4 groups: co...

Full description

Bibliographic Details
Main Authors:	Remon Rofaeil, Sabreen Ahmed, Haitham Bahaa, Ahmad Mahran, Nermeen Welson, Walaa Abdelzaher
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2022-11-01
Series:	Iranian Journal of Basic Medical Sciences
Subjects:	anti-apoptotic anti-inflammatory sitagliptin toll-like receptor 4 uterine ischemia
Online Access:	https://ijbms.mums.ac.ir/article_21108_e57ff6f9d2fb1481522198206c9f666e.pdf

Similar Items

Study on Anti-inflammatory and Anti-oxidative Stress Mechanism of Sitagliptin: a Dipeptidyl Peptidase-4 Inhibitor
by: ZHU Jing, XIE Ji, HU Xiaoxia
Published: (2025-04-01)

Dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates inflammation and autophagy in mice hindlimb ischemia–reperfusion injury
by: Marwa Abdeltawab Mohammed, et al.
Published: (2024-12-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes
by: Yan Tong, et al.
Published: (2023-04-01)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
by: Aleksander Sergeevich Ametov, et al.
Published: (2015-10-01)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020-04-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
by: Kannan Sridharan, et al.
Published: (2025-01-01)

The durability of sitagliptin in elderly patients with type 2 diabetes
by: Hsieh CJ, et al.
Published: (2014-11-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study
by: Yuya Tsurutani, MD, PhD, et al.
Published: (2017-01-01)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
by: Masahiro Fukuda, et al.
Published: (2019-03-01)

Adverse cardiac events of hypercholesterolemia are enhanced by sitagliptin in sprague dawley rats
by: Henry A. Palfrey, et al.
Published: (2024-07-01)

Oxidative stress markers in liver in streptozocin-induced diabetic rats: effects of metformin and sitagliptin
by: Şamil Öztürk, et al.
Published: (2020-12-01)

Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study
by: Takehiro Sugiyama, et al.
Published: (2024-11-01)

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles
by: Afzal Haq Asif, et al.
Published: (2018-05-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

The Impact of Sitagliptin on Sodium Valproate-Induced Autism in a Mouse Model
by: Ahmed Sudan Abbas, et al.
Published: (2024-09-01)

Cardioprotective Effect of Quercetin and Sitagliptin in Doxorubicin-Induced Cardiac Toxicity in Rats
by: Aziz TA
Published: (2021-03-01)

Corrigendum: Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis
by: Hongwei Shi, et al.
Published: (2021-11-01)

Sitagliptin-induced hiccups: A rare side effect
by: Prabhat Agrawal, et al.
Published: (2022-01-01)

Regulation of Adropin by Sitagliptin monotherapy in participants with newly diagnosed type 2 Diabetes
by: Qiu Wang, et al.
Published: (2022-12-01)

Effects of quercetin, sitagliptin alone or in combination in testicular toxicity induced by doxorubicin in rats
by: Ahmed ZA, et al.
Published: (2019-09-01)

Assessment of Factors Affecting Therapeutic Response of the DPP-4 Inhibitor Sitagliptin in A Sample of Iraqi Type 2 Diabetic Patients
by: Ahmad Nazar Jawad, et al.
Published: (2024-07-01)

Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study
by: Harmanjit Singh, et al.
Published: (2018-01-01)

Synergistic effects of sitagliptin and losartan against fipronil-induced hepatotoxicity in rats
by: Sara T. Elazab, et al.
Published: (2021-07-01)

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes
by: Beljić-Živković Teodora, et al.
Published: (2016-01-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Chromatographic study of sitagliptin and ertugliflozin under quality-by-design paradigm
by: Sunitha Gurrala, et al.
Published: (2023-06-01)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
by: Yong Kyun Cho
Published: (2018-09-01)

The Protective Effect of Anethole against Renal Ischemia/Reperfusion: The Role of the TLR2,4/MYD88/NFκB Pathway
by: Maged Elsayed Mohamed, et al.
Published: (2022-03-01)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
by: Saba Sayari, et al.
Published: (2018-09-01)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
by: Cristina Mega, et al.
Published: (2017-01-01)

Development and validation of RP HPLC method for determination of metformin and sitagliptin in bulk and pharmaceutical dosage form
by: Kavitha D., et al.
Published: (2017-04-01)

Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
by: Haitham G. Zakaraia, et al.
Published: (2023-11-01)

Practical Asymmetric Synthesis of Sitagliptin Phosphate Monohydrate
by: Haoling Gao, et al.
Published: (2018-06-01)

Noncardiac pulmonary edema induced by sitagliptin treatment
by: Tahir Belice, et al.
Published: (2014-01-01)

Neuroprotective Effects of Garlic: A Review
by: MATHEW BC, et al.
Published: (2008-01-01)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01)

Sitagliptin therapy improves myocardial perfusion and arteriolar collateralization in chronically ischemic myocardium: A pilot study
by: Sharif A. Sabe, et al.
Published: (2023-06-01)